Salicylic Acid
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Salicylic Acid: Papillary conjunctivitis
One-Sentence Summary
Salicylic acid is a keratolytic and anti-inflammatory agent, widely used on the skin for acne, seborrheic dermatitis, warts, corns and fungal skin infections, and also listed for inflammatory joint conditions and allergic rhinitis. The TxGNN model predicts it may be effective for papillary conjunctivitis, with a very high score but no clinical trials and no publications currently supporting this direction. This is a model-only prediction, and the evidence is too weak to justify moving forward at present.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Papillary conjunctivitis |
| TxGNN Prediction Score | 0.9988 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available. Based on known information, salicylic acid is a salicylate, and it is proposed to act through inhibition of COX enzymes and reduced prostaglandin synthesis. However, no public bioactivity data confirm this at a specific molecular target. Its effect on the skin is mainly keratolytic and anti-inflammatory.
The link to the new indication is plausible but indirect. Salicylic acid is associated with allergic rhinitis, and papillary conjunctivitis shares an allergic/atopic inflammatory component. This overlap is the only basis for the prediction, and it is not supported by any trial or publication.
There is also a practical concern. Topical salicylates are irritants, and the existing Indian products are for skin use (ointments, gels, serums, face washes). None are suited to the eye, so a new ophthalmic formulation and its safety work would be needed. The very high prediction score should be read as a model signal, not as proof of benefit.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
There are 20 valid single-ingredient registrations and no cancelled ones. The main five are listed below. Approved indication text is not recorded in the licence data.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 89442 | Furr 20% Vitamin C Skin Face Serum | Serum, 30 ml bottle | Not recorded |
| 88999 | Furr 2% Salicylic Anti Acne Face Serum | Serum, 30 ml bottle | Not recorded |
| 234301 | Vedasol 30mg Gel (Cipla Ltd) | Gel, 60 g tube | Not recorded |
| 31996 | Benzosil Ointment | Ointment, 25 g tube | Not recorded |
| 201510 | SA 20 Ointment | Ointment, 25 g tube | Not recorded |
Safety Considerations
- Drug Interactions: One pharmacology-based entry was found, involving the acid-sensing ion channel ASIC3 (a target interaction, not a drug-drug interaction). No interaction severity level is available.
- Ocular concern: Topical salicylic acid carries a risk of irritation, which is a major obstacle for any use on the eye surface.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the model score and an indirect allergic-inflammation argument. There are no trials or publications, the mechanism of action is not established, and ocular irritation risk is a significant concern. The other nine predicted indications are also model-only. Most (for example, rare skeletal dysplasias) have no credible mechanistic link and are probably TxGNN model (deep learning) artifacts. Of these, only spondyloarthropathy has plausible class-level support (NSAIDs), which could justify a focused literature review.
To proceed, the following is needed:
- Package insert warnings and contraindications (a blocking gap for safety screening)
- Detailed mechanism-of-action data
- A systematic literature search on salicylates in allergic and papillary conjunctivitis
- Ocular tolerability and formulation feasibility assessment (no eye-appropriate route is currently available)
- Preclinical evidence for the ocular indication before any clinical planning
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.